Arthur Wong and Andy Wang break down Johnson & Johnson’s (JNJ) strong quarterly results and raised full‑year guidance despite a muted stock reaction. They explain how the company is navigating the Stelara patent cliff by shifting patients to next‑generation therapies, with oncology emerging as a key growth driver. The discussion also weighs ongoing talc litigation risk against JNJ’s strong balance sheet and ability to continue investing heavily in R&D.